Monopar Therapeutics Inc. (MNPR)
Monopar Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wilmette, IL, US. The stock last traded at $85.23, down 4.06% on the session, giving a market capitalisation of $571.0M. On trailing twelve-month figures it carries a trailing P/E of -36.43, a net margin of 0.0%. Its beta of 1.50 implies it has historically moved more than the broad market.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Monopar Therapeutics Inc. is most often compared with the following Healthcare names: